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Conclusion. Monotherapy with 1,25DHC significantly pro-1,25-Dihydroxyvitamin D3 shows strong and additive immuno-
longs survival of renal allografts and preserves graft functionmodulatory effects with cyclosporine A in rat renal allotransplants.
in rats. A combination of 1,25DHC and CsA caused an additiveBackground. Vitamin D3 and its metabolites have long been
effect on graft survival with differential regulation of pro- andfound to exert immunosuppressive effects both in vivo and
anti-inflammatory cytokines, as compared to 1,25DHC admin-in vitro. The present study investigated the effect of 1,25-
istration alone.dihydroxycholecalciferol (1,25DHC) on vascularized renal al-
lografts in rats.
Methods. Three days prior to transplantation, two groups
of animals were subjected to 1,25DHC (1 g/kg/day IP) and Throughout the 1990s, transplantation has seen a surgea low calcium diet, which was continued until the end of the
of synthetic and naturally occurring compounds with im-experiments. Recipient organs were removed and single allo-
munosuppressive properties. The rationale for this searchgrafts were transplanted in a high responder strain combination
(ACI→ Lewis). Following transplantation, low-dose cyclospor- is the development of an optimal drug regimen with
ine A (3.2 mg/kg/day CsA) administration was started in two highly selective immunosuppressive properties and mini-
experimental groups of recipients (one group receiving 1,25 mal side effects. Among those compounds, sterols likeDHC additionally) whereas the control allograft recipients re-
corticosteroids and the hormonally active vitamin D me-ceived no immunosuppression (control III). Graft survival and
tabolite, 1,25 dihydroxy cholecalciferol (1,25DHC), arerenal function was monitored until death or the end of experi-
ments and allograft rejection was assessed histologically using physiologically occurring molecules with immunomodu-
the Banff classification. latory effects in humans [1]. To date, vitamin D has not
Results. 1,25DHC significantly prolonged allograft survival
been not used in clinical practice because of its hypercal-in comparison to control III (9.6  1 vs. 5.7  0.2 days; P 
cemic effects. Nevertheless, the immunomodulatory ef-0.009). In addition, a combination of 1,25DHC and low-dose
CsA increased allograft survival compared to CsA administra- fects of 1,25DHC have been studied intensively in lectin-
tion alone (24  0.9 vs. 13  0.3 days; P  0.008). 1,25DHC or antigen-activated lymphocytes in vitro as well as in
preserved renal creatinine clearance and decreased proteinuria autoimmune disease models [2, 3]. Thus, 1,25DHC inhib-
in comparison to control III, and the combination of 1,25DHC
its T helper subset (Th1) functions and attenuates theand low-dose CsA again showed an additive effect on preserva-
secretion of interleukin 2 (IL-2) and interferon  (IFN-)tion of renal function. 1,25DHC and low-dose CsA both de-
creased interleukin (IL)-2 and IL-12 expression levels in serum [4]. Furthermore, 1,25DHC specifically inhibits in a time
and allografts, and a combination treatment produced the and dose-dependent fashion the generation of cytotoxic
strongest attenuation of IL-2 and IL-12 expression. In addition, natural killer cells and this effect can be attenuated by1,25DHC increased IL-4 and IL-10 expression levels in allo-
administration of exogenous IL-2 [5]. Similarly, Meehan,grafts, whereas CsA alone did not alter IL-4 and IL-10 expres-
Kerman and Lemiere have shown that 1,25DHC pre-sion. In contrast, combination of 1,25DHC and low-dose CsA
showed a significant increase in IL-10 expression levels whereas vents the generation of cytotoxic T cells and promotes
IL-4 expression was not elevated. T-suppressor cell activity in an in vitro model of allograft
response [6]. Moreover, 1,25DHC induces an arrest in
the G1 phase of the T-cell cycle and induces apoptosisKey words: immunosuppression, graft survival, cytokine regulation,
transplantation, cell cycle, vitamin D. in stimulated T lymphocytes whereas exogenous IL-2
reverted both the cell cycle block and apoptosis [7].Received for publication September 12, 2000
In addition, it was recently reported that 1,25DHCand in revised form June 18, 2001
Accepted for publication August 16, 2001 reduces IL-12 expression in macrophages and dendritic
cells [8, 9]. These results indicate that 1,25DHC may 2002 by the International Society of Nephrology
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days prior to and following transplantation [14]. Tap
water was given ad libitum. Recipient animals (male Lewis
rats) were divided into three control and three experi-
mental groups (N  6 to 9/group). Control I were sub-
jected to isograft transplantation (Lewis → Lewis) and
vehicle administration only. Control II consisted of iso-
graft recipients receiving daily intraperitoneal injections
of 1,25DHC, starting three days prior to and following
transplantation until harvesting of organs. Control III
underwent allotransplantation (ACI → Lewis) and re-
ceived daily intraperitoneal vehicle injections only. Ex-
perimental animals (EXP) I received allotransplantation
and daily intraperitoneal injections of 1,25DHC. EXP II
animals were provided with allotransplantation and low
dose cyclosporine A (CsA) administration, whereas
EXP III animals were subjected to allotransplantation
and a combination of intraperitoneal low-dose CsA and
1,25DHC injections.
Immunosuppressive therapy
Vitamin D3. The bioactive compound 1,25DHC (Ro-Fig. 1. Flow chart outlining the different control and experimental groups.
caltrol; Roche Pharma, Basel Switzerland) was solubi-
lized in ethanol and diluted in saline before being injected
into recipients. Administration in allograft recipients was
started three days prior to and following transplantationexert beneficial effects in situations where a Th1 T-cell
differentiation arises, and thus may improve outcome until harvesting of organs. A daily dosage of 1 g/kg was
found to be effective in previous studies with rat cardiacin allogenic transplant models. Other data suggest that
derivatives of vitamin D also may potentiate the effect allografts [14], and was chosen for all animals receiving
1,25DHC. Based on our previous experiments with a ratof calcineurin inhibition in vitro and in vivo [10–12]. We
therefore investigated the immunosuppressive proper- animal model, intraperitoneal administration of 1,25DHC
was preferred over oral vitamin D3 intake for two mainties of 1,25DHC as a sole anti-rejection treatment as
well as in combination with a calcineurin inhibitor in an reasons. First, oral food consumption was inconsistent
during the first three to four days following transplanta-arterialized rat renal transplant model. Following trans-
plantation, graft function and survival were assessed and tion [15]. Second, animals were housed in pairs (two
animals per cage) in the central animal facility. Thus,expression levels of pro- (IL-2, IL-12) and anti-inflam-
matory cytokines (IL-4, IL-10) were determined. Fur- oral administration of 1,25DHC by incorporation into
the daily diet would have resulted in an unpredictablethermore, allograft rejection was estimated histologically
and classified according to the Banff 97 criteria [13]. In dosage per animal.
Cyclosporine A. Cyclosporine A (Sandimmune in-addition, osteopontin expression levels were assessed in
allografts in order to investigate whether vitamin D ex- jection grade) was obtained from Novartis Pharma (Basel,
Switzerland) and diluted in saline. CsA was given IP aterts all immunomodulatory effects at a set of traditional
inflammatory foci or whether vitamin D also modulates a dosage of 3.2 mg/kg/day starting perioperatively and
continuing until harvest of organs. The dose of CsA wasalternate events in the course of allograft lifespan.
chosen based on the reports of others [16].
METHODS Kidney transplantation experiments
Animals and experimental design In order to create a life-sustaining model, a single kidney
transplant model with bilateral recipient nephrectomy wasAnimal experiments were performed in accordance
with the national guidelines for the care and use of labo- used. For transplantation, recipients were anesthetized
with pentobarbitone sodium IP (50 mg/kg body weight).ratory animals and were approved by the local authori-
ties (Fig. 1). Male inbred Lewis and ACI rats (250 to After a median laparotomy, both kidneys were removed
and single allograft kidney transplantation with the ACI320 g), obtained from Harlan Sprague-Dawley (Horst,
The Netherlands), were used in a high responder strain (Rt.1.a) to LEWIS (RT.1.l) strain combination (Control
III, EXPs I to III) or single syngeneic transplants (Con-combination (ACI → Lewis). All animals were placed
on an experimental diet containing 0.47% calcium, seven trols I and II) were performed. Donor kidneys were rinsed
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with 5 mL Ringer’s lactate solution and transplanted or- Determination of renal osteopontin expression
by Western blot analysisthotopically. Renal vessels were anatomized using a 10/0
Prolene suture and ureters were connected via intralumi- Total protein was prepared by homogenizing graft kid-
nal polyethylene cuffs. Transplantation time ranged from ney tissue in 25 mmol/L Tris (pH 7.5), 50 mmol/L NaCl,
15 to 20 minutes and was not different between groups. and 10 mmol/L ethylenediaminetetraacetic acid (EDTA)
After transplantation, all animals were monitored and containing protease inhibitors (Boehringer Mannheim Bio-
kept in metabolic units for renal function analysis. Urine chemicals, Indianapolis, IN, USA). Aliquots containing
volume, urine protein and urea levels as well as serum 40 g of protein were subjected to sodium dodecyl sulfate
creatinine concentration and creatinine clearance were (SDS)/12% polyacrylamide gel electrophoresis (PAGE)
measured every second day. In addition, to study the ef- and transferred to nitrocellulose membranes. Membranes
fect of 1,25DHC on calcium metabolism, serum calcium were incubated with a monoclonal anti-osteopontin anti-
levels were measured with a Hitachi multi-analyzer (Hi- body (Developmental Studies Hybridoma Bank, Univer-
tachi, Zurich, Switzerland) on day 3, 0, 5, 9, 14 and 21. sity of Iowa, Aimes, IA, USA) diluted 1:1000, washed and
In separate sets of experiments (N  6/group), renal subjected to chemiluminescence Western blotting using
allografts were taken for histology and cytokine determi- a commercially available blotting kit (Pierce Chemical
nation on day 0, 5, 9, 14 and 21 post-transplant. Histologi- Co., Rockford, IL, USA) and a horseradish peroxidase-
cal changes were graded according to the Banff 97 work- conjugated goat anti-rabbit antibody (Developmental
ing classification of renal allograft pathology, in a blinded Studies Hybridoma Bank). The intensity of the Western
fashion [13]. blot signal was quantified with a CCD camera (Fuji film
LAS-1000; Raytest, Urdorf, Switzerland) using the soft-
Determination of cytokines in serum and tissue ware AIDA 2.1 (Raytest, Urdorf, Switzerland) and nor-
homogenates (IL-2, IL-4, IL-10 and IL-12) by ELISA malized to -tubulin (H235) protein expression levels
Graft tissue and peripheral blood samples were har- (rabbit polyclonal IgG, 200 g/mL; Santa Cruz Biotech-
vested from transplanted animals at defined time points nology, Heidelberg, Germany) in order to equalize dif-
and subjected for ELISA assays for determination of ferences in protein loading.
individual IL’s as described by the manufacturer (Phar-
StatisticsMingen, San Diego, CA, USA). Homogenates from con-
tralateral donor kidneys as well as serum samples from Results are expressed as mean values  SD. Graft
recipient animals prior to grafting were assessed to deter- survival was calculated with the Kaplan-Meier product
mine baseline IL concentrations. Briefly, plates were limit estimator. Differences in survival rates between the
coated overnight with the capture antibody at 4C in 0.1 various groups were tested with the log rank test in a
mol/L carbonate buffer, pH 9.5 (1 g/mL for anti-IL-2, statistical package program (SPSS Statistical Software,
-4 and -10, PharMingen; and 1 g/mL for anti-IL-12, Bio- Chicago, IL, USA). For enzyme-linked immunosorbent
source, Camarillo, CA, USA). The coated plates were assay (ELISA), Western blot assays and kidney function
washed six times with 0.01 mol/L, pH 7.4 phosphate assessment differences between groups were analyzed
buffered saline with 0.05% Tween-20 (PBS-T). Samples by analysis of variance (ANOVA) with the Bonferroni
were incubated for two hours at 37C, washed six times correction. A probability of P 	 0.05 was considered
with PBS-T, and incubated for an additional two hours statistically significant.
with the biotylinated secondary antibody [biotylinated
monoclonal anti-rat antibody for IL-2, IL-4 and IL-10
RESULTS(PharMingen), in PBS-T and biotylinated polyclonal
Effect of 1,25DHC on survivalanti-rabbit antibody for rat IL-12 (Biosource USA)]. The
plates were washed six times and incubated for one hour Kidney isograft transplantation and vehicle adminis-
at room temperature with avidin-peroxidase (Sigma, St. tration (control I, N  6) did not lead to recipient death
Louis, MO, USA) 1:400 in PBS-T. The plates were or major graft dysfunction (Fig. 2). Similarly, isograft
washed and developed with ortho-phenylamine-diamine transplantation under 1,25DHC medication was well tol-
(Sigma) in 1% methanol with 0.003% hydrogen perox- erated and the graft recipients remained alive (control II,
ide. The reaction was stopped by the addition of 50 L N  6). In contrast, in a high responder strain combina-
of 8 N sulfuric acid and optical density (OD) was deter- tion (ACI→ LEW), vehicle administration (control III;
mined at 492 nm. All assays were performed in triplicate N  9) led to a mean survival of 5.7  0.2 days (range
for determination of interassay variability. A five point 5 to 6 days). 1,25DHC (EXP I) significantly increased
standard curve was run in triplicate with each assay. Opti- survival when compared to control III (mean 9.6  1.2
cal density values at each test point were corrected by sub- days, P 0.009). Low-dose CsA treatment (EXP II, N9)
prolonged survival in comparison to EXP I (mean 13 tracting OD readings obtained for carbonate buffer only.
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Fig. 2. 1,25-Dihydroxycholecalciferol (1,25DHC)
improved survival following renal allograft trans-
plantation Kaplan-Meier survival curves of rat
recipients of an orthotopic vascularized renal iso-
graft/allograft. Allografts were performed in the
high-responder ACI → Lewis rat strains combi-
nation. Animals treated with 1,25DHC survived
longer than animals receiving vehicle only. In the
combination regimen there was a strong additive
effect.
0.3 days, range 11 to 15 days; P  0.008). The combina- of the animals, whereas IL-4 was not detectable in the
tion of 1,25DHC with low-dose CsA (EXP III, N  9) plasma or in the intragraft homogenates (Fig. 4 A–G).
further increased survival (mean 24  0.9 days, range Pretreatment with 1,25DHC did not alter the cytokine
20 to 27 days) when compared to low-dose CsA only expression pattern prior to transplantation. Similarly,
(P 	 0.001). 1,25DHC administration (Control II) showed no effect
on the various cytokine expression patterns during the
Effect of 1,25DHC on graft function
experimental period in comparison to vehicle treated iso-
Isograft recipients (Control I) showed an unaltered graft recipients (Control I). On the fifth day following
graft function throughout the experiments as shown allograft transplantation, IL-2 levels rapidly increased in
by the creatinine clearance and urine protein excretion vehicle treated animals (Control III) both in serum and
values (Fig. 3). Administration of 1,25DHC did not in- kidney grafts, whereas the 1,25DHC treatment (EXP I)
fluence isograft function at all (Control II; data not prevented an increase of IL-2 levels until day 9 following
shown). Allograft transplantation without administra- the allograft transplantation. Administration of CsA alone
tion of immunosuppressive agents (Control III) led to or in combination with 1,25DHC did not increase IL-2
a rapid deterioration of graft function. 1,25DHC treat-
levels both on day 5 and day 9 (EXP II and III) comparedment decelerated the deterioration of creatinine clear-
to pre-transplantation values. However, the combinedance and prevented proteinuria significantly during the
administration of CsA and 1,25DHC caused a signifi-first seven days after transplantation when compared
cantly smaller increase in serum IL-2 levels on day 14with normal allograft rejection. Low-dose CsA adminis-
compared to CsA treatment alone (P 	 0.002, Fig. 4A).tration conserved creatinine clearance and prevented
Similar results were observed for IL-12 expression. Base-proteinuria until day 9 following allografting. Combined
line concentrations were identical at time of transplanta-administration of low-dose CsA and 1,25DHC preserved
tion (day 0) for all groups of animals. Allograft trans-renal function until the third week following allograft
plantation caused a significant increase in either serumtransplantation.
(P	 0.001) or kidney graft expression (P	 0.001) at day
Effect of 1,25DHC on IL-2, IL-4, IL-10 5. Intragraft concentration of IL-12 was tenfold increased
and IL-12 production when compared to peripheral levels. Administration of
1,25DHC significantly inhibited IL-12 expression bothPrior to transplantation (day 0), low levels of IL-2,
IL-10 and IL-12 concentrations were detectable in most in serum and allografts at day 5 (P 	 0.001) and day 9
Redaelli et al: 1,25DHC shows strong and additive immunomodulatory effects on vascularized rat renal allografts292
following allograft transplantation, whereas administra-
tion of CsA alone did not affect IL-10 expression levels
during the study period (Fig. 4 E, F).
Intragraft expression levels of IL-4 were unaltered
following transplantation with the exception of 1,25DHC
receiving allografts (EXP I), which showed a marked
increase five and nine days following transplantation
(Fig. 4G). Serum IL-4 expression levels were not detect-
able in any animals at all time points.
Effect of 1,25DHC on renal osteopontin expression
Osteopontin (OPN) protein levels on day 5 following
isografted transplantation (Control I and II) did not alter
(Fig. 5). In contrast, allografting caused a substantial up-
regulation of OPN protein expression in vehicle treated
animals (Control III) at day 5 whereas administration
of 1,25DHC (EXP I) decreased OPN expression levels
significantly (P 0.004). CsA treatment (EXP II) inhib-
ited renal OPN expression until day 9, while the com-
bined therapy with CsA and 1,25DHC (EXP III) led
to a reduction in OPN protein expression until day 14
following allografting (EXP III vs. EXP II, P 	 0.001).
Histological assessment of graft rejection
The Banff 97 grading for each group is shown in Ta-
ble 1. Control III (N  6) showed histological changes
compatible with severe acute rejection at day 5 such as
marked necrosis in the cortex, moderate-to-severe tubu-
lointerstitial mononuclear infiltrates and moderate-to-
severe intimal arteritis. In addition, two cases showed
transmural arteritis with fibrinoid changes and medial
smooth muscle necrosis (Fig. 6A). Furthermore, several
areas of tubular basement membrane destruction were
Fig. 3. 1,25DHC treatment improved the renal function of rats that were found. In the vitamin D3-treated group (EXP I), the histo-recipients of a renal allograft, according to serum creatinine clearance
logical alterations were less severe revealing trivial tubu-(A) and proteinuria (B). Animals treated with 1,25DHC showed signifi-
cantly improved renal function in a mono- and combination therapy lointerstitial inflammation and no signs of arteritis could
model. Values obtained in animal recipient of an isograft (Control I
II) be detected (Fig. 6B). Administration of CsA (EXP IIare shown in open triangles. The data represent the mean  SD of six
and III) lead to mild tubulointerstitial mononuclear in-animals per group. Symbols are: () isograft vehicle, Control I group;
() allograft vehicle, Control III group; () allograft 1,25DHC, Exp filtration at day 14 following allotransplantation. All allo-
I; () allograft CsA, Exp II; () allograft CsA 
 1,24DHC, Exp III. grafts of animals subjected to low-dose CsA only showed
severe intimal arteritis compromising	25% of the lumi-
nal area (Banff type IIB) or transmural arteritis with(P	 0.001; Fig. 4 C, D) when compared to vehicle treated
necrosis of medial smooth muscle cells (Banff type III)animals (Control III). A more pronounced attenuation of at day 14. In contrast, none of the allografts of the CsA/
IL-12 expression was achieved with low-dose CsA admin- 1,25DHC group were graded higher as Banff IIA.
istration and the most significant effect was observed with
a combination of low-dose CsA and 1,25DHC treatment. Toxicity
Interleukin-10 serum levels increased slightly five days A significant limitation to the use of vitamin D3 deriva-
following allotransplantation (Control III) whereas in- tives in transplantation is the development of hypocal-
tragraft expression levels remained unaltered. In con- cemia. Significant hypocalcemia was not observed in
trast, administration of 1,25DHC caused a significant 1,25DHC treated recipients. Serum calcium levels in re-
increase in IL-10 expression levels both in serum and cipients treated with 1,25DHC (Control II, Exp I and
allografts at day 5 compared to Control III (P 	 0.001) III) increased slightly but non-significantly increased
and a further increase in IL-10 expression levels was during the study period in comparison to animals not
noted at day 9. In comparison to controls, a lesser but still subjected to 1,25DHC (Table 2). Low-dose CsA admin-
significant increase in IL-10 concentrations were noted in istration achieved mean serum CsA levels of 245 
34 ng/mL.animals receiving a combination of 1,25DHC and CsA
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Fig. 4. Serum and intragraft cytokine expres-
sion levels. Evaluation of serum and kidney
interleukins at baseline and during the trans-
plant course. Expression levels of IL-2 (A,
serum and B, intragraft) were markedly de-
creased in animals receiving 1,25DHC and/or
low-dose CsA. Similar results were observed
for IL-12 expression (C, serum and D intra-
graft). In contrast, IL-10 expression was sig-
nificantly increased under 1,25DHC adminis-
tration whereas low-dose CsA did not alter
IL-10 expression levels (E, serum and F, intra-
graft). Serum IL-4 was not detectable but
1,25DHC caused a strong induction of intra-
graft IL-4 expression following allografting in
comparison to vehicle treated animals (G). In
contrast, low-dose CsA administration did not
alter IL-4 expression neither as single agent
treatment nor in combination with 1,25DHC
(G). The data represent the mean  SD of six
animals per group. Symbols are: () isograft
vehicle, Control I group; () allograft vehicle,
Control III group; () allograft 1,25DHC,
Exp I; () allograft CsA, Exp II; () allograft
CsA 
 1,24DHC, Exp III.
Table 1. Histological grading of acute allograft rejection according to the Banff 97 classification
Acute rejection type (n)*
Group Drug N Day 5 post-Tx day 9 post-Tx Day 14 post-Tx
Control III (allograft) Vehicle 6 IIA, IIB (3), III (2)
EXP I 1,25 DHC 1000 ng/kg 6 normal, borderline (5) IIA (2), IIB (2)
EXP II CsA 3.2 mg/kg 6 normal (2), borderline (4) borderline (2), IA (4) IIB (3), III (3)
EXP III CsA 3.2 mg/kg 
 1,25DHC 1000 ng/kg 6 normal, borderline (5) borderline (3), IA (3) IA, IB (2), IIA (3)
* Numbers in parentheses indicate the numbers of individuals graded for that type. Groups are defined in the text.
DISCUSSION tions of chronic rejection by inhibiting the inflammatory
response of aortic allografts [17]. Previously, we haveThe remarkable biological effects of vitamin D analogs
demonstrated that 1,25DHC inhibited neonatal as well asmake them prime immunosuppressive agents in a trans-
vascularized heart transplant rejections more effectivelyplant setting. For instance MC1288, a vitamin D analog,
than a high-dose CsA regimen [14]. Moreover, 1,25DHCprolonged cardiac and small bowel allograft survival in
rats and furthermore prevented histological manifesta- treated mice were less susceptible to infections and
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Fig. 5. Intragraft osteopontin protein expression Western blot analysis
comparing the effects of vehicle, single and combined administration
of 1,25DHC and low-dose CsA on renal osteopontin (OPN) expression.
Results are representative of six independent probes/group/day.-tubu-
lin structural protein was used as internal control. Relative osteopontin
expression levels were normalized to -tubulin values and shown as
OPN/-tubulin ratio. 1,25DHC caused a significant reduction of osteo-
pontin protein expression in renal allografts when administered either
as single agent or in combination with low-dose CsA. Symbols are: ()
isograft vehicle, Control I group; () allograft vehicle, Control III
group; () allograft 1,25DHC, Exp I; () allograft CsA, Exp II; ()
allograft CsA 
 1,24DHC, Exp III.
showed less bone loss than CsA treated animals [18]. The
Fig. 6. (A) Control allograft with transmural arteritis and fibrinoiddata presented here demonstrate that administration of
necrosis of the vessel wall. Note the severe interstitial mononuclear1,25DHC significantly prolonged renal graft survival in
infiltrate and the presence of tubulitis (arrows). One glomerulus is
a high responder strain combination in rats. Thus, our infiltrated by neutrophil granulocytes (dotted arrow). (B) Vitamin D3-
treated allograft showing mild interstitial mononuclear infiltrates andresults are in agreement with previous reports examining
questionable tubulitis (H&E, magnification 400).the effects of vitamin D3 analogs on heart, aortic and small
bowel allografts [17–19]. In contrast, Lemire et al could
not observe a difference in graft survival using a neonatal
non-vascularized murine heart transplantation model 1,25DHC could be used in combination with other immu-
[20]. Similarly, Jordan et al reported a minimal effect of nosuppressants in order to potentiate the anti-rejection
1,25DHC on skin graft survival and rat cardiac allograft therapy but minimize side effects. Additive effects of
survival [21]. Both studies found significant toxicity. One CsA in combination with derivatives of 1,25DHC have
reason for the controversial findings may be based on been reported in cardiac transplantation [12] as well as
differences in experimental setup, which limited the pos- in syngeneic islet grafts in spontaneously diabetic non-
sibility to compare these data. In addition, there are obese mice [11] and in skin allografts in mice [22]. Our
considerable differences in the route of 1,25DHC admin- results on rat renal allograft survival in animals subjected
istration and daily dosage used in these different studies. to a combination therapy of low-dose CsA and 1,25DHC
Furthermore, several studies used various analogs of revealed a superior survival compared to only single
1,25DHC with fewer calcemic effects, and therefore agent therapy. Thus, our data correspond well with previ-
higher doses were administered in some of these studies, ous reports and may confirm that vitamin D analogs are
which may explain the more pronounced effect on graft potent additive drugs for other immunomodulators [11,
survival [18, 20, 21]. 12, 22]. This is particularly relevant since many patients
In clinical transplantation, a high-dose vitamin D3 treat- are taking vitamin D supplementation in order to pre-
ment under close monitoring of urine and serum calcium vent bone loss following kidney transplantation.
levels might be used as an induction therapy to reverse the An important additional finding of our experiments
initial acute rejection episode and to conserve graft func- is that 1,25DHC markedly attenuated renal allograft re-
jection. Grafts in animals receiving vitamin D3 showedtion. Alternatively, the immunosuppressive effect of
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Table 2. Calcium assessment
Serum calcium levels mg/L  SD
Pre-study
Group Drug N Day 3 Day 0 post-Tx Day 5 post-Tx Day 9 post-Tx Day 14 post-Tx
Isograft control I Vehicle 6 936.3 937.6 865.1 959.5 948.9
Isograft control II 1,25DHC 1000 ng/kg 6 948.9 984.1 995.3 1028.9 1035.2
Allograft control III Vehicle 12 922.9 914.4 8710.2 (6)
EXP I 1,25DHC 1000 ng/kg 12 956.4 974.9 1059.1 (10) 1036.3 (4)
EXP II CsA 3.2 mg/kg 6 915.9 942.3 897.4 925.3 935.1
EXP III CsA 3.2 mg/kg 
 1,25DHC 1000 ng/kg 6 943.3 986.1 994.1 1049.3 1057.3
Numbers in parentheses indicate the numbers of individual survivors determined. Serum calcium assessment in rats that received renal syngeneic and allograft
1,25DHC did not significantly alter serum calcium levels while under a low calcium diet during the early and late phases of the transplant course.
significantly less severe intimal arteritis whereas control senting cells, it also affects maturing dendritic cells, lead-
ing to enhanced IL-10 secretion upon activation by CD40allografts were graded as severe stages of acute rejection.
Moreover, vitamin D3 treatment was associated with a sig- ligation [9]. Our study also detected an increase of IL-10
expression levels in all rats medicated with 1,25DHC.nificant decrease in osteopontin expression following al-
lografting. In the past, there has been considerable con- Several recent studies have shown that IL-10 plays a
pivotal role in allograft rejection and that increased IL-10cern that active vitamin D might have a direct impact
on tubulointerstitial and glomerular integrity by affect- expression levels may enhance allograft survival [29–33].
However, it has been shown that 1,25DHC increasesing the responses to tubular injury [23]. In our study,
long-term vitamin D3 administration to isograft recipi- IL-4 protein and transcription levels and that the immu-
noregulatory effects of 1,25DHC are much less effectiveents did not impair renal function in isograft recipients
even after three weeks of continuous administration. In in IL-4-deficient mice, suggesting that IL-4 production
is a significant mediator in the action of vitamin D3 onaddition, there was no tubular or glomerular cell injury
detectable histologically and osteopontin expression was the immune system [34]. Therefore, we have determined
the differential expression of IL-4 and IL-10 in our exper-not altered. Similarly, Schwarz et al documented that
1,25DHC is able to reduce progression of glomeruloscle- imental groups and could observe that allografts in recip-
ients subjected to 1,25DHC showed significantly in-rosis and albuminuria in subtotal nephrectomized rats
[24]. Furthermore, administration of various vitamin D creased levels of IL-4. Thus, our results provide further
evidence that 1,25DHC exerts immunomodulatory ef-analogs in mice for over one year did not cause kidney
damage as revealed by extensive macroscopic and micro- fects by shifting the immune response from the Th-1
pathway to the Th-2 response, and that Th-2 relatedscopic autopsy studies [25].
In our study, 1,25DHC significantly improved allograft cytokines such as IL-4 and IL-10 may be involved in
graft tolerance.function as indicated by the superior creatinine clearance
and decreased urine protein excretion early and late in In a subsequent set of experiments, we examined the
effects of a combined administration of low-dose CsAthe transplant course. In the present study we adminis-
tered intraperitoneal 1,25DHC to prevent inconsistent and 1,25DHC on cytokine expression, since 1,25DHC
seems to interfere at a downstream level of calcineurindrug intake between individual animals during the first
days post-transplant, as we have preliminarily observed in the T-cell activation cascade [10]. Combination ther-
apy of CsA and 1,25DHC resulted in the strongest Th-1in our experiments. Therefore, the administration route
and the dose were based on previous experience [15]. Al- cytokine inhibition. In addition, IL-10 expression levels
significantly increased whereas IL-4 expression did notthough an orally given vitamin D regimen comes closer
to the clinical practice of vitamin D supplementation, alter in comparison to single CsA administration. The
explanations for this observation remain speculative. Itwe used the intraperitoneal regimen in all control and
experimental groups to ensure compatibility between may be hypothesized that a combination of 1,25DHC and
CsA has an additive effect on Th-1 cytokine inhibition.individual groups during the study period.
Consistent with previous findings from in vitro and in Alternatively, 1,25DHC could influence alternate path-
ways in the T-cell activation cascade, which may explainvivo studies, 1,25DHC caused a marked inhibition of
both IL-2 and IL-12 cytokine expression in renal allo- the differences in cytokine expression. Our results are
in contrast to the observation of Cantorna et al, whograft recipients [8, 25–28]. At the cellular and molecular
level, vitamin D not only targets helper T-cell activity reported that up-regulation of IL-4 and the subsequent
generations of Th-2 type responses are mandatory for theby inhibiting the secretion of IL-2 and by suppressing
the secretion of pro-Th1 cytokine IL-12 by antigen pre- immunoregulatory effects of vitamin D3 [34]. Therefore,
Redaelli et al: 1,25DHC shows strong and additive immunomodulatory effects on vascularized rat renal allografts296
13. Racusen LC, Solez K, Colvin RB, et al: The Banff 97 workingfurther experiments shall provide a more detailed insight
classification of renal allograft pathology. Kidney Int 55:713–723,into the characteristics of 1,25DHC mediated immuno- 1999
regulatory mechanisms and its effects on Th-1 and Th-2 14. Hullett DA, Cantorna MT, Redaelli C, et al: Prolongation of
allograft survival by 1,25-dihydroxyvitamin D3. Transplantation 66:related cytokine expression.
824–828, 1998Taken together, our results indicate that 1,25DHC is a 15. Cantorna MT, Hayes CE, DeLuca HF: 1,25-Dihydroxycholecal-
potent immunosuppressant in renal transplantation and ciferol inhibits the progression of arthritis in murine models of
human arthritis. J Nutr 128:68–72, 1998may serve as a dose-reducing agent in CsA immunosup-
16. Jiang H, Sakuma S, Fujii Y, et al: Tacrolimus versus cyclosporinpressive regimen. When the hypercalcemic effects of
A: A comparative study on rat renal allograft survival. Transplant
1,25DHC can be circumvented by a long-term low cal- Int 12:92–99, 1999
17. Johnsson C, Tufveson G: MC 1288—a vitamin D analogue withcium diet, 1,25DHC might prove a valuable adjunct in
immunosuppressive effects on heart and small bowel grafts. Trans-the armamentarium of immunosuppressant agents.
plant Int 7:392–397, 1994
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